ArticleSurgery open science2025
Timely staged hepatectomy following transarterial embolization versus emergency hepatectomy for spontaneous hepatocellular carcinoma rupture.
Article in Surgery open science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy and safety of timely staged hepatectomy (SH) following transarterial embolization (TAE) versus emergency hepatectomy (EH) for spontaneous rupture of hepatocellular carcinoma (SR-HCC). Methods: Between January 2018 and December 2023, 109 patients with SR-HCC were admitted to our center receive SH (34 cases) or EH (75 cases). Performing 1:1 optimal matching propensity score matching (PSM) analysis, resulting in 34 patients in SH group and 34 patients in EH group. We compared perioperative data, peritoneal metastasis rates, recurrence rates, complication rates, and long-term survival outcome between the two matched groups. Results: After PSM, baseline characteristics were well balanced between the SH and EH groups (standardized mean difference [SMD] < 0.1). Compared with the matched EH group, the SH group had a shorter intraoperative hepatic vascular clamping time, significantly less perioperative blood loss and transfusion volume, and a lower in-hospital mortality rate ( Conclusion: Compared with EH, SH demonstrates superior perioperative safety, characterized by less surgical trauma and lower in-hospital mortality, without increasing postoperative complications and the risk of peritoneal metastasis. Therefore, SH may be considered the preferred treatment for SR-HCC, especially in cases of hemodynamic instability or impaired hepatic functional reserve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.